Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA's written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The FDA's support is a significant milestone for Lantern Pharma as it refines its clinical development strategy for LP-300. By targeting a specific genetic subset of never-smoker patients—those with the EGFR exon 21 L858R mutation—the company aims to improve trial outcomes and potentially accelerate approval. This precision medicine approach leverages Lantern's proprietary RADR platform, which uses AI and machine learning to identify patient populations most likely to benefit from its therapies.
For patients, this news brings hope for more effective treatment options. Never-smokers with advanced lung adenocarcinoma often have limited choices after kinase inhibitors fail, and LP-300 combined with chemotherapy could address an unmet medical need. The regulatory clarity from the FDA may also reduce development risks and timelines, potentially leading to faster market access if the trial succeeds.
Lantern Pharma is a clinical-stage precision oncology company. Its pipeline includes LP-184, LP-284, and LP-300. The company also offers withZeta.ai, a multi-agentic AI co-scientist platform, commercially available as a subscription-based research platform. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The full press release is available at https://ibn.fm/Rxklm. For more information about Lantern Pharma, visit their newsroom at https://ibn.fm/LTRN.
